Cellectis - רווח נקי למניה ב-12 החודשים האחרונים CLLS

Serving as the primary valuation tool, this chart on GURU.Markets demonstrates the profit dynamics of Cellectis S.A. (CLLS), which stands at -14.20. The business relies on global cryo-logistics for biomaterial preservation, which supports high margins. Cellectis S.A. (CLLS) is implementing affordable allogeneic CAR-T therapies. However, severe side effects and stringent regulatory oversight create a threat of liquidity shortages.

The market evaluates Cellectis S.A. (CLLS) through the lens of high clinical trial volatility and regulatory barriers. This metric measures the annual earnings per share dynamics over a rolling period, reflecting the actual speed of capital scaling. By analyzing the current EPS YoY TTM growth rate, an investor can gauge the effectiveness of the company's efforts to combat liquidity shortages. A stable trend here confirms the business model's resilience to potential cash flow gaps.